Making Sense of Dual HER2-Targeting in Early Breast Cancer?
نویسندگان
چکیده
منابع مشابه
Targeting HER2 in breast cancer: overview of long-term experience
The ability to probe diseases at the genomic level has improved our understanding and enhanced the treatment of breast cancer. One important finding relates to the HER2 oncogene which encodes a novel transmembrane receptor that, when overexpressed, appears to confer growth and survival advantages to breast tumor cells. This fortuitous discovery enabled researchers to develop agents which could ...
متن کاملDual inhibition of HER2 in breast cancer treatment.
In The Lancet, José Baselga and colleagues present results from the phase 3 NeoALLTO trial, a pivotal investigation of dual anti-HER2 therapy for neoadjuvant treatment of breast cancer. The investigators used a straightforward approach to assess whether combination treatment with the antibody trastuzumab and the tyrosine kinase inhibitor lapatinib was better than single-agent treatment. 455 wom...
متن کاملTargeting alternative pathways in HER2-positive breast cancer.
Trastuzumab (Herceptin) has dramatically changed the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A phase III trial of firstline trastuzumab with various chemotherapy regimens compared with chemotherapy alone demonstrated a significant improvement in survival (25.1 vs 20.3 months) and overall response (50% vs 32%).1 This study resulted in the approval of ...
متن کاملTargeting HER2 in brain metastases from breast cancer.
For many types of cancers, therapy aimed at a specific molecular target remains in the realm of clinical research. However, for breast cancer, rational therapeutics is routinely practiced in the clinic. For many years, oncologists have used tamoxifen to selectively treat women with estrogen receptorpositive breast cancer. Clinicians now screen breast cancer for HER2 overexpression, which occurs...
متن کاملDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%-20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. How...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI Journal of the National Cancer Institute
سال: 2014
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/dju259